SB-247853 is a highly selective serotonin 5-HT2C receptor inverse agonist which was under development for the treatment of major depressive disorder but was never marketed. Its affinities (Ki) were found to be 0.50 nM for the serotonin 5-HT2C receptor, 60 nM for the serotonin 5-HT2B receptor, and 1,300 nM for the serotonin 5-HT2A receptor. Hence, it shows 120-fold selectivity for the serotonin 5-HT2C receptor over the serotonin 5-HT2B receptor and 2,600-fold selectivity for the serotonin 5-HT2C receptor over the serotonin 5-HT2A receptor. The drug reverses the hypolocomotion induced by the serotonin 5-HT2C receptor agonist meta-chlorophenylpiperazine (mCPP) in rodents. It is orally active. The drug produced orthostatic intolerance in healthy human volunteers during the first dose-escalation clinical study. Subsequently, it was found to cause substantial hypotension (low blood pressure) and presyncope (pre-fainting symptoms) in the tilt table test. It was concluded based on these findings that the serotonin 5-HT2C receptor is involved in regulating the cardiovascular system. SB-247853 was first described in the scientific literature by 2000. It was developed by GlaxoSmithKline. The drug reached phase 1 clinical trials prior to the discontinuation of its development in 2005.
See also Serotonin 5-HT2C receptor antagonist List of investigational antidepressants
References


